Hanall Biopharma Co Ltd
009420
Company Profile
Business description
Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology.
Contact
12 Bongeunsa-ro 114-gil
Daewoong Building, 3rd Floor
Gangnam-gu
Seoul
KORSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
323
Stocks News & Analysis
stocks
ASX healthcare share remains undervalued ahead of earnings
Margin recovery remains the key driver for this ASX healthcare share.
stocks
Alphabet earnings: Strong AI monetization continues to spearhead results
We maintain our fair value estimate for wide-moat Alphabet.
stocks
AMD: We’re pleased with Anthropic Partnership ahead of advancing AI event
We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,941.50 | 32.70 | -0.36% |
| CAC 40 | 8,324.52 | 25.43 | 0.31% |
| DAX 40 | 24,923.96 | 160.84 | 0.65% |
| Dow JONES (US) | 51,711.65 | 506.93 | -0.97% |
| FTSE 100 | 10,672.54 | 33.37 | 0.31% |
| HKSE | 24,963.23 | 247.58 | -0.98% |
| NASDAQ | 25,137.69 | 553.21 | -2.15% |
| Nikkei 225 | 64,611.15 | 1,811.45 | -2.73% |
| NZX 50 Index | 13,772.29 | 23.02 | -0.17% |
| S&P 500 | 7,408.30 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,772.30 | 23.40 | -0.27% |
| SSE Composite Index | 3,814.20 | 62.58 | -1.61% |